Get the Stockscreener App
4.72
0.63%
-0.03
After Hours:
4.60
-0.12
-2.54%
Galectin Therapeutics Inc stock is traded at $4.72, with a volume of 224.22K.
It is down -0.63% in the last 24 hours and down -5.60% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$4.75
Open:
$4.77
24h Volume:
224.22K
Relative Volume:
0.74
Market Cap:
$302.36M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-6.4658
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+9.01%
1M Performance:
-5.60%
6M Performance:
+265.89%
1Y Performance:
+82.95%
1-Day Range:
$4.56
$4.7779
1-Week Range:
$4.375
$4.8468
52-Week Range:
$0.726
$6.55
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.72 | 304.29M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Can machine learning forecast Galectin Therapeutics Inc. recoveryJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
Trend analysis for Galectin Therapeutics Inc. this weekQuarterly Investment Review & Reliable Volume Spike Alerts - newser.com
Galectin Therapeutics Inc Stock Analysis and ForecastMarket Depth Overview & Big Profit Low Trading - earlytimes.in
Galectin Therapeutics' (GALT) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Should Dividend Investors Consider Omnipotent Industries Limited in YEAREconomic Data Impact & Free Dashboard to Track Market Momentum - earlytimes.in
Is Galectin Therapeutics Inc a good long term investmentChart Pattern Recognition & Connect With Bulls, Avoid the Bears - earlytimes.in
Prevents Varices at 18 Months — Galectin Therapeutics to Present NAVIGATE Data at AASLD Nov 10 - Stock Titan
Will Galectin Therapeutics Inc. (PHPN) stock hit Wall Street targetsJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
How sentiment analysis helps forecast Galectin Therapeutics Inc.July 2025 Decliners & Verified Short-Term Plans - newser.com
Market reaction to Galectin Therapeutics Inc.’s recent newsQuarterly Market Review & Fast Gain Stock Trading Tips - newser.com
Is Galectin Therapeutics Inc. (PHPN) stock cheap by valuation metricsPortfolio Update Summary & Weekly Breakout Opportunity Watchlist - newser.com
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200 Day Moving Average – What’s Next? - Defense World
Will Galectin Therapeutics Inc. (PHPN) stock beat growth indexesJuly 2025 Summary & Daily Price Action Insights - newser.com
Analyzing Galectin Therapeutics Inc. with risk reward ratio charts2025 Technical Overview & Weekly Watchlist for Hot Stocks - newser.com
Using R and stats models for Galectin Therapeutics Inc. forecastingWeekly Trade Recap & Accurate Trade Setup Notifications - newser.com
Chart overlay techniques for tracking Galectin Therapeutics Inc.July 2025 Recap & Precise Swing Trade Alerts - newser.com
What drives Galectin Therapeutics Inc PHPN stock pricePrice Momentum Alerts & High Yield Market Growth - earlytimes.in
What drives Galectin Therapeutics Inc stock priceDouble Top/Bottom Patterns & Free Double Digit Growth Tips - earlytimes.in
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CALLICUTT JACK W | Chief Financial Officer |
Sep 12 '25 |
Sale |
6.44 |
8,706 |
56,054 |
7,614 |
| LEWIS JOEL | President and CEO |
Sep 12 '25 |
Option Exercise |
2.39 |
14,000 |
33,460 |
846,592 |
| LEWIS JOEL | President and CEO |
Sep 12 '25 |
Sale |
6.36 |
14,000 |
89,048 |
832,592 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):